Published OnlineFirst April 21, 2014; DOI: 10.1158/2326-6066.CIR-14-0053

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma F. Stephen Hodi, Donald Lawrence, Cecilia Lezcano, et al. Cancer Immunol Res 2014;2:632-642. Published OnlineFirst April 21, 2014.

Updated version Supplementary Material

Access the most recent version of this article at: doi:10.1158/2326-6066.CIR-14-0053 Access the most recent supplemental material at: http://cancerimmunolres.aacrjournals.org/content/suppl/2014/04/21/2326-6066.CIR-14-0053.DC1.html

Cited Articles

This article cites by 36 articles, 14 of which you can access for free at: http://cancerimmunolres.aacrjournals.org/content/2/7/632.full.html#ref-list-1

Citing articles

This article has been cited by 3 HighWire-hosted articles. Access the articles at: http://cancerimmunolres.aacrjournals.org/content/2/7/632.full.html#related-urls

E-mail alerts Reprints and Subscriptions Permissions

Sign up to receive free email-alerts related to this article or journal. To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [email protected]. To request permission to re-use all or part of this article, contact the AACR Publications Department at [email protected].

Downloaded from cancerimmunolres.aacrjournals.org on September 7, 2014. © 2014 American Association for Cancer Research.

Published OnlineFirst April 21, 2014; DOI: 10.1158/2326-6066.CIR-14-0053

Cancer Immunology Research

Research Article

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma F. Stephen Hodi1, Donald Lawrence4, Cecilia Lezcano10, Xinqi Wu1, Jun Zhou1, Tetsuro Sasada1, Wanyong Zeng1, Anita Giobbie-Hurder2, Michael B. Atkins11, Nageatte Ibrahim1, Philip Friedlander12, Keith T. Flaherty4, George F. Murphy5, Scott Rodig5, Elsa F. Velazquez7,9, Martin C. Mihm Jr5, Sara Russell6, Pamela J. DiPiro3, Jeffrey T. Yap3, Nikhil Ramaiya3, Annick D. Van den Abbeele3, Maria Gargano1, and David McDermott8

Abstract Ipilimumab improves survival in advanced melanoma and can induce immune-mediated tumor vasculopathy. Besides promoting angiogenesis, vascular endothelial growth factor (VEGF) suppresses dendritic cell maturation and modulates lymphocyte endothelial trafficking. This study investigated the combination of CTLA4 blockade with ipilimumab and VEGF inhibition with bevacizumab. Patients with metastatic melanoma were treated in four dosing cohorts of ipilimumab (3 or 10 mg/kg) with four doses at 3-week intervals and then every 12 weeks, and bevacizumab (7.5 or 15 mg/kg) every 3 weeks. Forty-six patients were treated. Inflammatory events included giant cell arteritis (n ¼ 1), hepatitis (n ¼ 2), and uveitis (n ¼ 2). On-treatment tumor biopsies revealed activated vessel endothelium with extensive CD8þ and macrophage cell infiltration. Peripheral blood analyses demonstrated increases in CCR7þ//CD45ROþ cells and anti-galectin antibodies. Best overall response included 8 partial responses, 22 instances of stable disease, and a disease-control rate of 67.4%. Median survival was 25.1 months. Bevacizumab influences changes in tumor vasculature and immune responses with ipilimumab administration. The combination of bevacizumab and ipilimumab can be safely administered and reveals VEGF-A blockade influences on inflammation, lymphocyte trafficking, and immune regulation. These findings provide a basis for further investigating the dual roles of angiogenic factors in blood vessel formation and immune regulation, as well as future combinations of antiangiogenesis agents and immune checkpoint blockade. Cancer Immunol Res; 2(7); 632–42. 2014 AACR.

Introduction CTLA4 blockade with ipilimumab improves survival in patients with metastatic melanoma when compared with a gp100 peptide vaccine (1) and in combination with dacarbazine chemotherapy when compared with dacarbazine alone (2). Efforts to further enhance the efficacy of immune checkpoint blockade through rational treatment combinations are needed. In pursuit of predictive markers, pretreatment levels of vascular endothelial growth factor (VEGF-A) influence clinical outcomes to ipilimumab therapy (3). Therefore, determinants Authors' Affiliations: Departments of 1Medical Oncology, 2Biostatistics, and 3Imaging, Dana-Farber Cancer Institute; 4Massachusetts General Hospital Cancer Center; Departments of 5Pathology and 6Surgery, Brigham and Women's Hospital; 7Tufts University; 8Beth Israel-Deaconess Medical Center, Boston; 9Miraca Life Sciences, Newton, Massachusetts; 10 University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 11 Lombardi Cancer Center Georgetown University, Washington, District of Columbia; and 12Mount Sinai Medical Center, New York, New York Note: Supplementary data for this article are available at Cancer Immunology Research Online (http://cancerimmunolres.aacrjournals.org/). Corresponding Author: F. Stephen Hodi, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215. Phone: 617-632-5053; Fax: 617-582-7992; E-mail: [email protected] doi: 10.1158/2326-6066.CIR-14-0053 2014 American Association for Cancer Research.

632

that may limit ipilimumab efficacy include immunosuppressive angiogenic factors such as VEGF. VEGF has profound effects on immune regulatory cell function, specifically inhibiting dendritic cell maturation and antigen presentation (4, 5). Furthermore, there is increasing evidence for the role angiogenic factors play in influencing lymphocyte trafficking across endothelia into tumor deposits (6). Previous studies have demonstrated the effects of ipilimumab on vessels feeding tumor deposits, resulting in an immune-mediated vasculopathy (7). As a result of CTLA4 blockade, granulocytes and lymphocytes infiltrate the endothelia, resulting in its destruction and tumor necrosis. The clinical efficacy of targeting VEGF-A and its effects on pathologic angiogenesis have been extensively studied with the use of bevacizumab (8–14), and these findings suggest a role in counteracting the immunosuppressive actions of VEGF. Given the effects on tumor vasculature witnessed in patients with melanoma being treated with ipilimumab and the known activity of bevacizumab, we conducted a phase I study to investigate the potential synergies of this combination in patients with metastatic melanoma.

Materials and Methods Study design and treatment The protocol (Supplementary Appendix A) was approved by the Dana-Farber/Harvard Cancer Center institutional review

Cancer Immunol Res; 2(7) July 2014

Downloaded from cancerimmunolres.aacrjournals.org on September 7, 2014. © 2014 American Association for Cancer Research.

Published OnlineFirst April 21, 2014; DOI: 10.1158/2326-6066.CIR-14-0053

Bevacizumab plus Ipilimumab

board, and all patients provided signed informed consent. Patient eligibility included measureable unresectable stage III or stage IV melanoma, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, adequate end-organ function. Exclusion criteria included central nervous system (CNS) metastases, prior treatment with ipilimumab or bevacizumab, history of autoimmune disease, melanoma involvement in the gastrointestinal tract, ulcerated skin lesions, or ongoing treatment with full-dose warfarin, heparin equivalent, nonsteroidal anti-inflammatory drugs, aspirin within 10 days of enrollment, or any medication that inhibits platelet function within 2 weeks before enrollment. Four cohorts of patients each received four doses of ipilimumab at 3-week intervals and then every 3 months, plus bevacizumab every 3 weeks (continuous): cohort 1, ipilimumab 10 mg/kg þ bevacizumab 7.5 mg/kg; cohort 2, ipilimumab 10 mg/kg þ bevacizumab 15 mg/kg; cohort 3, ipilimumab 3 mg/kg þ bevacizumab 7.5 mg/kg; cohort 4, ipilimumab 3 mg/kg þ bevacizumab 15 mg/kg (Supplementary Fig. S1). Cohorts that included 3 mg/kg were added following the approval of ipilimumab at this dose to gain safety data and experience. Patients were first enrolled in cohorts of five with 10 mg/kg of ipilimumab. The dose-limiting toxicity (DLT) period was 12 weeks. If 3 of 5 patients in cohort 1 did not experience a DLT, then the study was permitted to proceed to the next cohort. If 3 patients in cohort 3 experienced a DLT, the study was designed to stop. To ensure that toxicity at the maximum tolerated dose (MTD) was acceptable and to gain additional experience with this combination, an additional 12 patients were accrued at MTD. There was a 94% probability of dose escalation if the true rate of DLT was no more than 20%. If the true rate of DLT exceeded 50%, the probability of escalation was less than 50%. Statistical analysis Best overall response (BORR) was defined as the proportion of patients with complete or partial response at any time while on study. The disease-control rate (DCR) was the proportion of patients with complete response, partial response, or stable disease. Differences in response rates or DCR by cohort were assessed using the Fisher exact test. Time to progression (TTP), overall survival (OS), and duration of response were assessed using the method of Kaplan– Meier, with pointwise, 95% confidence intervals (CI) estimated using log[log(survival)] methodology. Equality of survival curves by cohort was assessed using the log-rank test. Comparisons of the incidences of adverse events by cohort according to CTCAE 3.0 System Class were conducted using the Fisher exact test. All P values were twosided, with statistical significance defined as P < 0.05. There were no corrections for multiple comparisons. Flow cytometry Peripheral blood samples from patients receiving ipilimumab alone on an expanded access study were obtained on Dana-Farber/Harvard Cancer Center review board–approved protocols and used for comparison with samples from the

www.aacrjournals.org

current trial. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque (GE Biosciences) density gradient centrifuge. Cells were stained with fluorescent conjugated antibodies, and analyzed on a FC500 FACS analyzer (Beckman Coulter). A total of 1  105 events were collected. FACS analysis results are expressed as percentages (CD4-PE Cy7, CD8PE Cy7, CD28-PerCP, and CD45RO-ECD antibodies were from Beckman Coulter, CCR7-FITC from R&D Systems, and CD57-PE from Abcam). Percentage increase (cutoff 5%) between pretreatment and posttreatment by 50% was considered a significant increase. Differences in the proportions increased between ipilimumab and ipilimumab plus bevacizumab groups were determined by the Fisher exact test. Immunohistochemistry Metastatic melanoma samples from patients that received ipilimumab plus bevacizumab (n ¼ 10) and ipilimumab alone (n ¼ 6) on an expanded access study were obtained before and after treatment initiation. Ipilimumab-alone samples were obtained from patients being treated on approved clinical trials. Posttreatment samples from both the current ipilimumab–bevacizumab trial and ipilimumab alone were obtained at the same time from the initiation of therapy, immediately following the completion of ipilimumab induction at approximately week 12. Biopsies of end-organs suspected of inflammatory events related to treatment were obtained whenever possible. Formalin-fixed paraffin-embedded tissue sections were stained for biomarkers that included CD3 (Dako; A0452; 1:250), CD8 (Dako; M7103; 1:100), CD20 (Dako; N1502; undiluted), Foxp3 (BioLegend; 320102; 1:50), and CD163 (Vector Laboratories; VP-C374; 1:500) to characterize immune infiltrates. To assess vessel morphology and activation, CD31 (Dako; N1596; undiluted) and E-selectin (Neuromics; MO20039; 1:50) antibodies were used. Humoral immune responses detected following treatment Antibodies presented in posttreatment sera were screened using ProtoArray Human Protein Microarray v5 (Invitrogen) according to the manufacturer's instructions. Antibody targets were identified by a Z factor of 0.4. The presence of galectin antibodies in the sera were confirmed by immunoblot analysis using recombinant human galectins-1, -3, and -9 (R&D Systems). To compare antibody levels as a function of treatment, galectin-1, -3, and -9 immunoblots (blocking 5% BSA) were incubated with pretreatment and posttreatment sera (1:2,000 dilution in PBS with 2% BSA) overnight, followed by horseradish peroxidase–conjugated goat anti-human IgG antibody (Invitrogen), and visualized with enhanced chemiluminescence. Densities of protein bands and backgrounds were quantified using NIH ImageJ software. After background subtraction, galectin antibody responses to treatment were determined by the formula: fold change ¼ (densitypost  densitypre)/densityPre. A fold change of 0.5 was considered a significant increase.

Cancer Immunol Res; 2(7) July 2014

633

Downloaded from cancerimmunolres.aacrjournals.org on September 7, 2014. © 2014 American Association for Cancer Research.

Published OnlineFirst April 21, 2014; DOI: 10.1158/2326-6066.CIR-14-0053

Hodi et al.

Figure 1. High-grade treatmentrelated adverse events. A, grade 4 events. ALT, alanine aminitransferase (SGPT); AST, aspartate aminotransferase (SGOT). B, grade 3 events. Eleven study patients had treatmentrelated, grade 3 events [23.9%, (95% exact CI, 13%–39%)]. Hematoxylin and eosin–stained, formalin-fixed, paraffin-embedded tissue sections showing temporal artery, cut in cross section, with transmural acute and chronic inflammation at 200 (C) and 400 (D) final magnification. E and F, skin with chronic inflammation intermixed with eosinophils within the mid-dermis at 400 (E) and 1,000 (F) final magnification. G and H, core of liver with acute and chronic inflammation including prominent eosinophils, at 400 (G) and 1,000 (H) final magnification.

634

Cancer Immunol Res; 2(7) July 2014

Cancer Immunology Research

Downloaded from cancerimmunolres.aacrjournals.org on September 7, 2014. © 2014 American Association for Cancer Research.

Published OnlineFirst April 21, 2014; DOI: 10.1158/2326-6066.CIR-14-0053

Bevacizumab plus Ipilimumab

Results

tory events revealed by posttreatment biopsies included giant cell (temporal) arteritis (Fig. 1C and D), dermatitis (palpable purpura; Fig. 1E and F), and eosinophilic hepatitis (Fig. 1G and H). There was one on-treatment death due to disease progression reported for a patient in cohort 3. The incidence of events per patient is summarized in Table 1.

Patients and treatment A total of 46 patients were treated (Fig. 1, CONSORT diagram). Five patients in cohort 1 were first treated without any DLTs. Five patients were then treated in cohort 2 without toxicities; therefore, cohort 2 (ipilimumab 10 mg/kg plus bevacizumab 15 mg/kg) was determined to be MTD. An additional 12 patients were treated at MTD. The study was amended to enroll 12 patients each to cohorts 3 and 4 following the regulatory approval of ipilimumab at 3 mg/kg. Demographics, disease status, and prior treatment according to cohort are summarized in Supplementary Table S1. Patients were predominantly male (61%) with a median age of 58 years (range, 25–80). Eighty-nine percent of the patients had an ECOG performance status of 0. Forty-one patients (89%) had stage IV melanoma and 5 (11%) had unresectable, stage III disease. Thirteen (28%) patients had prior chemotherapy and radiation, 7 (15%) had radiation and no chemotherapy, 16 (35%) had chemotherapy and no radiation, and 8 (17%) had neither radiation nor chemotherapy. The median number of sites of disease was 3 (range, 1–8): 83% had lymph node disease, 63% had lung, and 61% had soft tissue. The median follow-up based on patients alive at the time of data retrieval was 11.8 months (range, 2.6–42.5).

Study outcomes Treatment with ipilimumab plus bevacizumab resulted in morphologic changes in intratumoral endothelia with rounded and columnar CD31þ cells compared with pretreatment or posttreatment samples from patients receiving ipilimumab alone (Fig. 2A and Supplementary Fig. S2). To illustrate variations in pathologic responses observed, examples of intermediate and no response are provided in Supplementary Fig. S3. Increased expression of E-selectin as a function of therapy was observed with combined treatment relative to ipilimumab alone, revealing further biochemical evidence for endothelial activation by the addition of bevacizumab. Concentrated CD31 staining was observed at the interendothelial junctions (Supplementary Fig. S2). Pathology review further revealed that these endothelial changes were associated with extensive immune cell infiltration of tumors. Vessel density was not affected significantly by bevacizumab therapy. With pathologic examination of immune infiltrates associated with treatment, significant trafficking of CD8þ T cells and CD163þ dendritic macrophages (Fig. 3) across the tumor vasculature was witnessed in ipilimumab plus bevacizumab posttreatment biopsies that was qualitatively increased in comparison with that elicited by ipilimumab alone. There was minimal change in FoxP3þ cellular composition. We next sought to identify altered immune responses resulting from bevacizumab plus ipilimumab combination therapy. To pursue functional changes, flow cytometry detecting T-cell phenotypes in the peripheral blood demonstrated enhancement in CCR7þ/CD45ROþ populations for CD4þ (Fig. 4A) and CD8þ (Fig. 4B) T cells (individual responses Supplementary Fig. S4). Bevacizumab plus ipilimumab significantly increased circulating memory cell phenotypes compared with

Adverse events Toxicities (regardless of attribution) for the first 12 weeks representing the dose-limiting window are presented in Supplementary Table S2. Two patients experienced DLTs, 1 from cohort 3 and 1 from cohort 4. No DLTs occurred in cohort 1 or 2. There were no treatment-related deaths. All 46 patients reported adverse events. The most commonly reported adverse events (any grade) were fatigue (n ¼ 14), rash/desquamation (n ¼ 15), headache (n ¼ 16), and cough (n ¼ 17). Supplementary Table S3 presents the grade 3 and grade 4 events for each dose level for all events and those events possibly, probably, or definitively related. High-grade (grade 3/4) treatment-related adverse events for any time on study are summarized in Fig. 1. Grade 4 events included proteinuria and hepatic toxicities. Thirteen patients experienced high-grade adverse events. High-grade inflamma-

Table 1. Number of treatment-related adverse events per patient

Overall Cohort 1 2 (MTD) 3 4

N

Mean

SD

Min

Median

Max

13

1.4

0.7

1.0

1.0

3.0

1 6 3 3

2.0 1.2 1.7 1.3

— 0.4 1.2 0.6

2.0 1.0 1.0 1.0

2.0 1.0 1.0 1.0

2.0 2.0 3.0 2.0

NOTE: Worst grade of reported adverse event/toxicity per patient. Thirteen patients had treatment-related, grade 3 or 4 events [28.3%, (95% exact CI: 16%–43%)]. For patients with treatment-related, grade 3 or 4 events, the table summarizes the number per patient. Adverse events classified as "not related" are included. Grades: 1, mild; 2, moderate; 3, severe; 4, life-threatening; 5, death.

www.aacrjournals.org

Cancer Immunol Res; 2(7) July 2014

635

Downloaded from cancerimmunolres.aacrjournals.org on September 7, 2014. © 2014 American Association for Cancer Research.

Published OnlineFirst April 21, 2014; DOI: 10.1158/2326-6066.CIR-14-0053

Hodi et al.

Figure 2. Intratumoral blood vessel changes from treatment with bevacizumab plus ipilimumab in subcutaneous melanoma deposits. A, characterization of tumor-associated vasculature before and while on therapy. Endothelial cells lining small vessels within melanomas of ipilimumab plus bevacizumab–treated patients were rounded and columnar as assessed by hematoxylin and eosin (H&E) and CD31 staining, in contrast with pretreatment samples and on-treatment samples from patients receiving ipilimumab alone (column to extreme right; v, vessel). Scale bar, 50 microns. Endothelial cells in tumor deposits of þ patients receiving ipilimumab plus bevacizumab were also associated with increased expression of E-selectin, and adhesion and diapedesis of CD8 T cells. Enlarged central panels highlight the focally occlusive appearance of this endothelial activation [top, H&E; bottom, CD31; inset, E-selectin)]. Base membrane of vessels approximated by dotted lines.

ipilimumab alone (Fig. 4C). Furthermore, analyses with posttreatment sera using protein arrays identified galectin-1 and galectin-3 in 2 of 4, and 3 of 4 patients, respectively (Z factor ¼ 0.49 and 0.7 for galectin-1, and 0.58, 0.83, and 0.87 for galectin3). Galectin-9 was not included in the protein array. Given its biologic significance in immune regulation, galectin-9 was included in subsequent analyses. The presence of anti-galectin antibodies in sera was further confirmed by immunoblot using recombinant proteins (Fig. 4D). Patients who received ipilimumab plus bevacizumab had a significantly higher number of responses to galectins-1, -3, and -9 than patients who received ipilimumab alone (Fisher exact P ¼ 0.02; Fig. 4E). Efficacy The median follow-up at the time of this analysis was 17.3 months (95% CI, 11.1–30.2 months). Thirty-nine (85%) patients stopped treatment, and 7 patients remained on study. Nine patients (23%) discontinued treatment due to toxicity, 29 (74%) due to progressive disease, and 1 (3%) due to withdrawal of consent. The median number of cycles patients received was 7 (range, 2–37). The 12-week response for the entire treated patient population was 10.9% (95% exact CI, 4%–24%; highest cohort 2, 17.6%). Clinical activity is shown in Fig. 5. BORR was 19.6% [95% exact CI, 9%–34%; highest cohort 2, 29.4% (95% exact CI, 10%– 56%); 1 complete response; Supplementary Table S4]. In addition to examples of pseudoprogression (Fig. 6), delayed best responses (Supplementary Fig. S5) were observed. Response

636

Cancer Immunol Res; 2(7) July 2014

kinetics for all patients are presented in Supplementary Fig. S6A and for cohort 2 (MTD) in Supplementary Fig. S6B. DCR for all patients was 67.4% [95% exact CI, 52%–81%; cohort 2, 76.5% (95% exact CI, 50%–93%)]. There were no statistical differences in the response or DCR between cohorts. Most durable responses achieved best response after months of therapy. One patient in cohort 2 (MTD) experienced 7 months of stable disease before a partial response and subsequently had a complete response beginning 17 months following the initiation of therapy. Eleven patients in cohorts 1 and 2 are alive, months after discontinuation of therapy. The median TTP was 9.0 months [95% CI, 5.5–14.5 months; longest cohort 2, 14.5 months (95% CI 3.8–¥); Supplementary Fig. S7]. There were no differences in progression-free survival (PFS) by cohort (logrank P ¼ 0.32). Radiographic evidence for early metabolic antitumor responses without significant anatomic response was exemplified with PET/CT imaging (Fig. 6A–D). Transient increases in lesion size with decreased density before gradual decrease in size with subsequent imaging (Fig. 6E–H) were observed in a number of patients, consistent with pseudoprogression. Thirty (65%) patients were alive at the time of data retrieval. Kaplan–Meier estimates for TTP and OS are shown in Supplementary Fig. S7. Median OS was 25.1 months [95% CI, 12.7– ¥; cohort 2, 25.1 months (95% CI, 9.6–¥)]. There were no differences in OS by cohort (log-rank P ¼ 0.98). The Kaplan– Meier estimate of 1-year OS was 79% (95% CI, 62%–89%), and

Cancer Immunology Research

Downloaded from cancerimmunolres.aacrjournals.org on September 7, 2014. © 2014 American Association for Cancer Research.

Published OnlineFirst April 21, 2014; DOI: 10.1158/2326-6066.CIR-14-0053

Bevacizumab plus Ipilimumab

Figure 3. Histologic changes in tumor deposits resulting from treatment with bevacizumab plus ipilimumab. A, phenotypic characterization of immunecell infiltrates in biopsies from responders before and after initiation of therapy. Tumors after initiation (ON) of ipilimumab–bevacizumab therapy þ þ þ were characterized as compared with pretreatment samples (PRE). Significant infiltration by CD3 CD8 T cells and CD163 macrophages þ with minimal change in Foxp3 component was observed. The enlarged panels (center) emphasize the tumor-infiltrating architecture of the immune response (top left, skeletal muscle). In contrast, patients treated only with ipilimumab showed a lesser degree of immune-cell infiltration while on therapy. The two ipilimumab–bevacizumab specimens are subcutaneous tissues, and the ipilimumab-alone specimen was from the oropharyngeal submucosa.

6-month TTP was 63% (95% CI, 47%–75%). The lower bounds of both confidence intervals exceed those of Korn and colleagues (15).

Discussion The influences on immunologic effects witnessed with the addition of bevacizumab to ipilimumab reveal novel mechanisms of action for bevacizumab in patients. First, morphologic and biochemical alterations in the tumor vasculature resulted in endothelial activation associated with qualitative increases in lymphocyte and myeloid/monocyte cell trafficking into tumor deposits. The monocytes had extensive dendritic processes. These patterns of immune infiltrates for some patients were associated with transient increases in lesion size with decreased density before gradual decrease in size with subsequent imaging. Detailed characterization of these infiltrates and cellular functions are areas for future investigation. Vessel changes were similar to those observed in high endothelial venules (HEV) found in secondary lymphoid organs and associated with lymphocyte extravasation (16). Such endothelial

www.aacrjournals.org

appearances correlated with the ability of lymphocytes to migrate into tissues. E-selectin expression induced by bevacizumab facilitates lymphocyte adhesion and rolling (17). In addition, CD31 influences adhesive and signaling functions for vascular cellular extravasation (18, 19). Specifically, the concentration of CD31 staining at the interendothelial junctions of bevacizumab plus ipilimumab–treated specimens indicates vessels adapted for efficient lymphocyte trafficking (20). These results are consistent with previous observations of anti-VEGF treatment increasing lymphocyte tumor infiltrates in adoptive therapy models (21, 22). Further evidence for immunologic changes by the combination was demonstrated in the peripheral blood through increasing circulating memory T cells resulting from the addition of bevacizumab. This provides a definitive role for bevacizumab in effecting broad changes in the circulating immune composition. Furthermore, the coordinated T- and B-cell responses witnessed previously with checkpoint blockade (23, 24) are confirmed by the increased antibody recognition of the galectin family members. This finding suggests that the concerted effects of combination therapy

Cancer Immunol Res; 2(7) July 2014

637

Downloaded from cancerimmunolres.aacrjournals.org on September 7, 2014. © 2014 American Association for Cancer Research.

Published OnlineFirst April 21, 2014; DOI: 10.1158/2326-6066.CIR-14-0053

Hodi et al.

Figure 4. Cellular and humoral immune responses in the peripheral blood are altered by the addition of bevacizumab to ipilimumab. All samples were obtained pretreatment and at week 12 at the completion of ipilimumab or ipilimumab– bevacizumab induction. A, example of changes as a function of treatment in þ þ þ þ CD4 CCR7 CD45RO and CD4  þ CCR7 CD45RO T-cell populations to ipilimumab plus bevacizumab treatment, compared with changes with ipilimumab treatment alone. B, example of changes þ as a function of treatment in CD8 þ þ þ CCR7 CD45RO and CD8  þ CCR7 CD45RO T-cell populations to ipilimumab plus bevacizumab treatment, compared with the responses to ipilimumab treatment alone. C, number of patients with melanoma who have at þ þ least 50% enhancement in CD4 /CD8 þ þ þ þ CCR7 CD45RO and CD4 /CD8  þ CCR7 CD45RO T-cell populations following treatment with ipilimumab (3 mg/kg), or ipilimumab (3 mg/kg) plus bevacizumab, or ipilimumab (10 mg/kg) plus bevacizumab.  , P < 0.05 between ipilimumab and ipilimumab plus  bevacizumab; , P < 0.01. D, representative immunoblots of antibody responses in 4 bevacizumab plus ipilimumab–treated patients to a total of zero, one, two, or three galectins. Arrows, increased antibody levels in posttreatment sera samples. Galectin-1, -3, and -9 proteins were mixed together and equally loaded and separated by gel electrophoresis. Following transfer onto a membrane, strips were incubated with equally diluted pretreatment and posttreatment sera. Density analysis using NIH ImageJ software confirmed the increases in densities of the indicated bands after subtracting background taken from nearby areas of each band. As in most of the cases, density change was seen in only one or two of the three galectins; protein(s) without density change served as loading controls. E, antibody responses to galectins in patients treated with bevacizumab plus ipilimumab and ipilimumab alone. Anti-galectin-1, anti-galectin-3, and anti-galectin-9 antibodies were detected in pretreatment and posttreatment patient sera by immunoblot analyses. Percentages of patients with increased levels of antibodies to a total of zero, one, two, or three galectins in bevacizumab plus ipilimumabtreated patients (n ¼ 45) and ipilimumabalone patients (n ¼ 18). Density of each band was measured using NIH ImageJ software and the antibody fold change was calculated using the formula: fold change ¼ (densityPost  densityPre)/densityPre. Antibody levels were considered as increased when the fold change  0.5.

638

Cancer Immunol Res; 2(7) July 2014

Cancer Immunology Research

Downloaded from cancerimmunolres.aacrjournals.org on September 7, 2014. © 2014 American Association for Cancer Research.

Published OnlineFirst April 21, 2014; DOI: 10.1158/2326-6066.CIR-14-0053

Bevacizumab plus Ipilimumab

Figure 5. Activity in treated patients by cohort according to RECIST criteria. Arrows, patients alive at the time of analysis; crosses, death; black bars, discontinuation of treatment other than due to progressive disease. Five patients came off trial due to toxicity requiring systemic steroids. One patient withdrew consent after week 12 without DLT. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

can result in additional immune recognition that extends implications for both immune regulation and angiogenesis. As the galectin family members are involved in tumor-cell invasion, metastases, and angiogenesis as well as immune regulation, it will be important to define in future studies the functions of these antibodies and their potential therapeutic roles. In preclinical animal models and in humans, VEGF has been associated with altered antitumor immune responses, including the suppression of dendritic-cell maturation (4, 5), proliferation of regulatory T cells, inhibition of T-cell responses (25), and accumulation of myeloid-derived suppressor cells (26–28). In patients with colorectal cancer, bevacizumab improved the antigen-presenting capacity of circulating dendritic cells (29). The increase in dendritic-cell infiltrates associated with the current study suggests a role for VEGF blockade in influencing the association of antigen-presenting cell with tumor cells and their maturation. This reveals an additional mechanism for bevacizumab on immune function in the context of checkpoint blockade. Inflammatory toxicities were generally higher than expected with ipilimumab alone, but remained manageable. These included rare vasculitic events suggesting immune recognition of unique sets of antigens (30) and eosinophilicdriven processes. Importantly, there did not seem to be an increased incidence of dermatologic or gastrointestinal side effects such as colitis, which are most concerning for ipilimumab. As such, the combination of blocking CTLA4 and VEGF-A may broaden the recognized antigen repertoire. Recent clinical trials reporting survival outcomes for patients with metastatic melanoma have led to regulatory

www.aacrjournals.org

approval for ipilimumab and vemurafenib. Phase II trials of ipilimumab revealed 2-year survival rates of 24.2% to 32.8% (31, 32). In patients who had received at least one prior therapy, ipilimumab, when compared with a gp100 peptide vaccine, improved the median OS from 6.4 to 10.1 months (1). OS in previously treated patients with melanoma receiving vemurafenib was 15.9 months (33). In the current phase I trial combining bevacizumab and ipilimumab, the clinical activity was favorable compared with ipilimumab alone. As all but one partial response occurred in cohorts 1 and 2 (10 mg/kg ipilimumab), the ipilimumab dose may influence the efficacy when ipilimumab is combined with bevacizumab. The median survival of the entire 46-patient cohort was greater than 2 years with significant antitumor activity witnessed at MTD. With the lower bounds of both confidence intervals exceeding those of Korn and colleagues (15), this combination is worthy of further pursuit. Importantly, these results establish a mechanistic foundation for combining antiangiogenesis with immune checkpoint blockade for cancer treatment. Antiangiogenic therapy for cancer has traditionally provided a means to limit the blood supply and improve delivery of antineoplastic agents to tumor sites. When combined with chemotherapy or interferon, bevacizumab has proved efficacious at improving the outcomes of patients with colorectal cancer, renal cell carcinoma, non–small cell lung cancer, breast cancer, ovarian cancer, and glioblastoma multiforme (8–12, 34, 35). For many tumors, hypoxia creates a microenvironment of inhibitory inflammatory cells (27, 36). The role of angiogenic factors in suppressing inflammation to promote vessel growth has increasingly been recognized in the context of tumor immunology (36). The ability to counteract the dual function

Cancer Immunol Res; 2(7) July 2014

639

Downloaded from cancerimmunolres.aacrjournals.org on September 7, 2014. © 2014 American Association for Cancer Research.

Published OnlineFirst April 21, 2014; DOI: 10.1158/2326-6066.CIR-14-0053

Hodi et al.

Figure 6. Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. An early metabolic response is noted in a dominant left hepatic metastasis. E, axial contrast-enhanced CT image obtained at baseline demonstrates a solitary heterogeneous hypodense lesion in segment II of the liver, consistent with a metastatic deposit. F, axial contrast-enhanced CT obtained 4 months after treatment demonstrates slight increase in the lesions with interval decrease in density (from 40 HU to 19 HU, approximately 50%), consistent with treatment effect. The increase in size represents pseudoprogression. G and H, follow-up CT scans obtained 6 and 36 months after the start of treatment demonstrate gradual decrease in size of the metastatic deposit.

of angiogenic factors in promoting vessel growth and suppressing immune responses is provided in the current study by the parallel effects on host immunity and tumor vasculature. Mechanisms defining the roles for bevacizumab in the context of immune checkpoint blockade were uncovered. The combination provoked inflammatory events in patients, promoted memory cells circulating in the peripheral blood, enhanced intratumoral trafficking of effector cells, and improved endogenous humoral immune responses to galectins. Further investigation is needed to evaluate the mechanistic basis of bevacizumab activity and the full impact of clinical activity. Continued development of immune checkpoint and antiangiogenic combination therapies are warranted for the treatment of melanoma and other cancers.

640

Cancer Immunol Res; 2(7) July 2014

Disclosure of Potential Conflicts of Interest F.S. Hodi has received research support from Bristol-Myers Squibb and Genentech, has an ownership interest (including patents) in IP licensed to Bristol-Myers Squibb (as per institutional IP policy), and is a consultant/advisory board member for Bristol-Myers Squibb and Genentech. M.B. Atkins is a consultant/advisory board member for Bristol-Myers Squibb and Genentech. E.F. Velazquez and M.C. Mihm serve as directors for SKADA, Inc., and are consultant/advisory board members for Melasciences and Caliber ID. D. McDermott is a consultant/advisory board member for Bristol-Myers Squibb. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions Conception and design: F.S. Hodi, A. Giobbie-Hurder, Development of methodology: F.S. Hodi, W. Zeng, G.F. Murphy, J.T. Yap Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): F.S. Hodi, D. Lawrence, C. Lezcano, X. Wu, J. Zhou, T. Sasada, W. Zeng, M.B. Atkins, N. Ibrahim, P. Friedlander, K.T. Flaherty,

Cancer Immunology Research

Downloaded from cancerimmunolres.aacrjournals.org on September 7, 2014. © 2014 American Association for Cancer Research.

Published OnlineFirst April 21, 2014; DOI: 10.1158/2326-6066.CIR-14-0053

Bevacizumab plus Ipilimumab

G.F. Murphy, E.F. Velazquez, M.C. Mihm, S. Russell, P. DiPiro, J.T. Yap, A.D. Van den Abbeele, M. Gargano, D. McDermott Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): F.S. Hodi, D. Lawrence, C. Lezcano, X. Wu, T. Sasada, W. Zeng, A. Giobbie-Hurder, P. Friedlander, K.T. Flaherty, G.F. Murphy, S. Rodig, E.F. Velazquez, M.C. Mihm, S. Russell, P. DiPiro, J.T. Yap, N. Ramaiya, A.D. Van den Abbeele, D. McDermott Writing, review, and/or revision of the manuscript: F.S. Hodi, D. Lawrence, C. Lezcano, X. Wu, A. Giobbie-Hurder, M.B. Atkins, N. Ibrahim, P. Friedlander, K. T. Flaherty, G.F. Murphy, S. Russell, P. DiPiro, J.T. Yap, N. Ramaiya, A.D. Van den Abbeele, M. Gargano, D. McDermott Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): F.S. Hodi, J. Zhou, W. Zeng, A.D. Van den Abbeele Study supervision: F.S. Hodi

Grant Support This study was funded by NIH CA143832 (to F.S. Hodi) and 1R012CA158467 (to F.S. Hodi and G.F. Murphy), the Melanoma Research Alliance (to F.S. Hodi), the Sharon Crowley Martin Memorial Fund for Melanoma Research (to F.S. Hodi), and the Malcolm and Emily Mac Naught Fund for Melanoma Research (to F.S. Hodi) at the Dana-Farber Cancer Institute, Genentech/Roche, and Bristol-Myers Squibb. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 26, 2014; revised March 28, 2014; accepted April 7, 2014; published OnlineFirst April 21, 2014.

References 1.

2.

3.

4. 5.

6.

7.

8. 9.

10.

11. 12. 13.

14. 15.

16.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–23. Robert C, Thomas L, Bondarenko I, O'Day S, Weber JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517–26. Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS, et al. Pretreatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2014; 2:127–32. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001;23:263–72. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998;160:1224–32. Kandalaft LE, Motz GT, Busch J, Coukos G. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. Curr Top Microbiol Immunol 2011;344:129–48. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100: 4712–7. Braghiroli MI, Sabbaga J, Hoff PM. Bevacizumab: overview of the literature. Expert Rev Anticancer Ther 2012;12:567–80. Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: an update. Pharmacotherapy 2012;32: 1095–111. Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors– a meta-analysis and systematic review. PLoS ONE 2013;8: e51780. Miyake TM, Sood AK, Coleman RL. Contemporary use of bevacizumab in ovarian cancer. Expert Opin Biol Ther 2013;13:283–94. Yeung Y, Tebbutt NC. Bevacizumab in colorectal cancer: current and future directions. Expert Rev Anticancer Ther 2012;12:1263–73. Khasraw M, Simeonovic M, Grommes C. Bevacizumab for the treatment of high-grade glioma. Expert Opin Biol Ther 2012;12: 1101–11. Small AC, Oh WK. Bevacizumab treatment of prostate cancer. Expert Opin Biol Ther 2012;12:1241–9. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman Vj, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26: 527–34. Johnson-Leger C, Aurrand-Lions M, Imhof BA. The parting of the endothelium: miracle, or simply a junctional affair? J Cell Sci 2000; 113 (Pt 6):921–33.

www.aacrjournals.org

17. Borgstrom P, Hughes GK, Hansell P, Wolitsky BA, Sriramarao P. Leukocyte adhesion in angiogenic blood vessels. Role of E-selectin, P-selectin, and beta2 integrin in lymphotoxin-mediated leukocyte recruitment in tumor microvessels. J Clin Invest 1997;99: 2246–53. 18. Marelli-Berg FM, Clement M, Mauro C, Caligiuri G. An immunologist's guide to CD31 function in T-cells. J Cell Sci 2013;126:2343–52. 19. Ma L, Cheung KC, Kishore M, Nourshargh S, Mauro C, Marelli-Berg FM. CD31 exhibits multiple roles in regulating T lymphocyte trafficking in vivo. J Immunol 2012;189:4104–11. 20. Muller WA. The role of PECAM-1 (CD31) in leukocyte emigration: studies in vitro and in vivo. J Leukoc Biol 1995;57:523–8. 21. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010;70:6171–80. 22. Kandalaft LE, Motz GT, Duraiswamy J, Coukos G. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev 2011;30: 141–51. 23. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kture A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008;105:3005–10. 24. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 2008;105:20410–5. 25. Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, et al. VEGFA-VEGFR pathway blockade inhibits tumorinduced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013;73:539–49. 26. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253–68. 27. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013;73:2943–8. 28. Terme M, Colussi O, Marcheteau E, Tanchot C, Tartour E, Taieb J. Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol 2012;2012:492920. 29. Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar R, et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008;57: 1115–24. 30. Weyand CM, Goronzy JJ. Giant cell arteritis as an antigen-driven disease. Rheum Dis Clin North Am 1995;21:1027–39. 31. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155–64. 32. O'Day SJ, Maio M, Chiarion-Sileni V, Gajweski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in

Cancer Immunol Res; 2(7) July 2014

641

Downloaded from cancerimmunolres.aacrjournals.org on September 7, 2014. © 2014 American Association for Cancer Research.

Published OnlineFirst April 21, 2014; DOI: 10.1158/2326-6066.CIR-14-0053

Hodi et al.

patients with pretreated advanced melanoma: a multicenter singlearm phase II study. Ann Oncol 2010;21:1712–7. 33. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707–14. 34. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391–400.

642

Cancer Immunol Res; 2(7) July 2014

35. Heitz F, Harter P, Barinoff J, Beutel B, Kannisto P, Grabowski JP, et al. Bevacizumab in the treatment of ovarian cancer. Adv Ther 2012;29: 723–35. 36. Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011;30:83–95.

Cancer Immunology Research

Downloaded from cancerimmunolres.aacrjournals.org on September 7, 2014. © 2014 American Association for Cancer Research.

Cancer Immunology Research

Correction

Correction: Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma In this article (Cancer Immunol Res 2014;2:632–42), which appeared in the July 2014 issue of Cancer Immunology Research (1), the panels of Fig. 1 are labeled incorrectly. The grade 4 toxicities should be labeled as A, and the grade 3 toxicities as B; B to G should be labeled C to H. The authors regret this error.

Reference 1. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014;2:632–42. Published OnlineFirst August 5, 2014. doi: 10.1158/2326-6066.CIR-14-0141 Ó2014 American Association for Cancer Research.

www.aacrjournals.org

923

Bevacizumab plus ipilimumab in patients with metastatic melanoma.

Ipilimumab improves survival in advanced melanoma and can induce immune-mediated tumor vasculopathy. Besides promoting angiogenesis, vascular endothel...
2MB Sizes 3 Downloads 3 Views